Merck Boosts Outlook As Q3 Results Top Estimates

Biopharmaceutical company Merck & Co., Inc. reported Thursday profit for the third quarter that declined 29 percent from last year, hurt by hefty increase in R&D expenses, despite 14 percent sales growth. However, both adjusted earnings per share and quarterly sales topped analysts' estimates.

from RTT - Top Story https://ift.tt/fx6eJa2
via IFTTT